瑞舒伐他汀对糖尿病大鼠早期动脉粥样硬化形成的影响

目的：观察他汀类调脂药物瑞舒伐他汀（Rosuvastatin）对2型糖尿病（type2diabetesmellitus,T2DM）大鼠早期动脉粥样硬化形成的影响,并探讨其可能的机制。方法：将45只雄性SD大鼠随机分为正常对照组（NC组）、2型糖尿病组（DM组）、2型糖尿病瑞舒伐他汀治疗组（DR组）,每组15只。以喂高糖高脂饮食方法建立SD大鼠糖尿病模型,DM组、DR组给予高糖高脂饮食1个月后腹腔注射25mg/kg链脲佐菌素;NC组给予普通饮食,注射枸橼酸缓冲液作为对照。在此基础上,DR组给予瑞舒伐他汀5mg/（kg.d）灌胃,NC组、DM组给予生理盐水灌胃。16周后测定各组大鼠总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）水平与稳态血糖（BG）、稳态胰岛素（PGI）浓度,用免疫组化法检测主动脉血管壁白细胞分化抗原40（clusterofdifferentiation 40,CD40）及基质金属蛋白酶-2（MMP-2）、激活蛋白-1（activator protein-1,AP-1）的表达水平。结果：DM组、DR组TC、TG、LDL-C与BG水平较NC组均显著升高（F=33.71~426.05,q=5.26~40.82,P〈0.01）,但2组间各指标比较差异无显著性（P〉0.05）。DR组CD40、MMP-2、AP-1表达水平和浸润的单核细胞数明显低于DM组（F=36.86~716.82,q=8.59~37.86,P〈0.05）,DR组主动脉内皮损伤明显轻于DM组。结论：瑞舒伐他汀能抑制CD40、MMP-2、AP-1表达和单核细胞浸润,防止早期AS形成。     

大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效观察

目的:研究大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的临床疗效。方法:选取2013年10月到2014年10月我院收治的老年冠心病合并高脂血症患者110例,按照随机数字表法将患者分为研究组和对照组,每组55例。两组患者均给予常规治疗方法进行治疗,对照组增加5 mg瑞舒伐他汀钙进行治疗,研究组增加20 mg瑞舒伐他汀钙进行治疗,均每天1次,晚餐后应用,治疗时间为4个月。比较治疗前后两组血脂水平(胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C))及高密度脂蛋白(HDL-C)及其达标率以及不良反应。结果:治疗后两组TC、TG以及LDL-C均显著降低,HDL-C显著升高,且研究组优于对照组,比较差异具有统计学意义(P0.05);研究组治疗后TC和LDL-C达标率显著高于对照组,两组比较差异具有统计学意义(P0.05);两组不良反应发生率比较差异无统计学意义(P0.05)。结论:大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症具有较好的临床疗效,能显著降低患者的血脂水平。     

瑞舒伐他汀钙对冠心病合并高脂血症患者血清hs-CRP及颈动脉内膜中层厚度的影响

目的:分析不同剂量瑞舒伐他汀钙治疗冠心病合并高脂血症患者的临床效果以及对患者血清hs-CRP和颈动脉内膜中层厚度(IMT)的影响。方法:选择2013年6月-2015年6月在我院接受治疗的冠心病合并高脂血症患者203例,根据用药剂量不同将其分为小剂量组(70例)、中剂量组(64例)及大剂量组(69例),分别采用口服瑞舒伐他汀钙5 mg/次/日、10 mg/次/日和20 mg/次/日进行治疗。观察并比较三组患者治疗前后血脂(TG,TC,LDL-C,HDL-C)、血清hs-CRP及IMT的变化情况。结果:治疗前,三组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值比较,差别均无统计学意义(P0.05);治疗后,三组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值均较治疗前降低,差异具有统计学意义(P0.05);大剂量瑞舒伐他汀钙组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值显著低于中剂量组和小剂量组,差异具有统计学意义(P0.05);中剂量组患者血清hs-CRP,TG,TC,LDL-C,HDL-C以及IMT值显著低于小剂量组,差异具有统计学意义(P0.05)。结论:瑞舒伐他汀钙能够改善冠心病合并高脂血症患者的血脂水平、降低血清hs-CRP及IMT,并且其疗效与药物剂量存在量效关系。     

泽泻对高脂高糖饮食大鼠肠道菌群多样性的影响

目的研究泽泻对高脂高糖饮食大鼠的降血脂作用与肠道菌群多样性的相关性,并测定高脂高糖饮食大鼠肠道菌群丰度与多样性的变化。方法将32只健康雄性SD大鼠随机分成正常组(control group,CON)、高脂高糖模型组(high-fat and high-sucrose diet group,HFS)、高脂高糖饲料加二甲双胍干预组(metformin treatment group,MET)和高脂高糖饲料加泽泻醇提取物干预组(Alisma orientale extract group,AOE)。每组8只,造模4周后分别灌胃给予相应药物,连续4周。CON组和HFS组灌胃给予生理盐水。检测血清TC、TG、LDL-C及HDL-C水平及其他指标,提取肠道菌群总DNA,分析肠道微生物的变化。结果 HFS组的TC、LDL-C水平明显高于CON组(Ps0.05),给药4周后,AOE组TC、LDL-C水平均显著性降低(Ps0.05)。高通量测序结果显示,AOE组中与脂质代谢、多聚糖生物合成与代谢相关的肠道菌群多样性及丰度增加显著,肠道菌群的生态环境得以改善,形成了新的肠道菌群稳态。结论泽泻醇提取物可以有效降低高脂高糖饮食大鼠的血脂水平,对其肝脏具有保护作用。泽泻醇提取物也能通过改变肠道菌群的丰度、多样性和功能类群等靶标进行脂质代谢调节。     

三种金花茶提取物降脂作用实验研究

目的:探讨金花茶浓缩液、金花茶乙酸乙酯/二氯甲烷提取物以及金花茶水提物对高脂血症小鼠血脂的调节作用。方法:将小鼠按照体重随机分成正常饮食组和高脂饮食组,分别给予正常饲料和高脂饲料喂食,4周后将高脂饮食小鼠按照体重以及血脂水平(TC)随机分成金花茶浓缩液组、金花茶乙酸乙酯/二氯甲烷提取物组、金花茶水提物组以及辛伐他丁组。3种金花茶提取物以及辛伐他丁混悬液连续灌胃10周,同时给予高脂饮食。末次给药后禁食不禁水12 h,摘眼球取血,检测血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、超氧化物歧化酶(SOD)以及丙二醛(MDA)。结果:与模型组相比,金花茶浓缩液和辛伐他丁能显著降低血清TC、TG、LDL-C水平(P0.01或P0.05),但是对HDL-C无明显调节作用;对血清中的AST、ALT、SOD以及MDA影响不大。金花茶乙酸乙酯/二氯甲烷提取物以及水体物对血清中的TC、TG、LDL-C、HDL-C、AST、ALT、SOD及MDA无明显的调节作用。结论:金花茶浓缩液对高脂血症小鼠的血脂具有良好的调节作用。     

葛根素对2型糖尿病大鼠的治疗作用*

目的:观察葛根素对2型糖尿病(T2DM)大鼠的治疗作用。方法:采用高糖高脂饲料喂养加一次性腹腔注射60 mg/kg链脲佐菌素的方法建立T2DM 大鼠模型,随机分为正常组,模型组,二甲双胍(40 mg/kg)组,葛根素低、中、高剂量(40,80,160 mg/kg)组,每组10只大鼠;造模成功后,灌胃给药4周,每周测量大鼠体重和空腹血糖(FBG),末次给药24 h后取血,收集血清,检测各组大鼠的血糖、血清甘油三酯(TG)、总胆固醇(TC) 、低密度脂蛋白-胆固醇(LDL-C)水平、高密度脂蛋白-胆固醇(HDL-C),血清天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)活性,血清尿素氮(BUN)、肌酐(SCr)、尿酸(UA)水平。结果:干预4周后,与正常组比较,模型组大鼠体重显著降低(P＜0.01),FBG,TC,TG,LDL-C,ALT,AST,BUN,SCr,UA均显著升高(P＜0.01),而HDL-C 显著降低(P＜0.01);与模型组比较,二甲双胍组和葛根素各剂量组大鼠体重均显著增加(P＜0.01),FBG,TC,TG,LDL-C,ALT,AST,BUN,SCr,UA均显著降低(P＜0.01),而HDL-C显著升高(P＜0.01)。结论:葛根素能够减少T2DM大鼠体重降低幅度,降低血脂、血糖水平,可用于T2DM的治疗。     

不同剂量瑞舒伐他汀联合通心络胶囊治疗冠心病合并高脂血症患者的疗效观察

目的:探讨不同剂量瑞舒伐他汀联合通心络胶囊治疗冠心病合并高脂血症患者的疗效。方法:按照随机数字表法将2017年4月至2018年5月内蒙古医科大学附属医院接诊的120例冠心病合并高脂血症患者分为低剂量联合组(5 mg瑞舒伐他汀+通心络胶囊)、中剂量联合组(10 mg瑞舒伐他汀+通心络胶囊)、高剂量联合组(20 mg瑞舒伐他汀+通心络胶囊),每组各40例,三组均治疗12周。比较三组患者的血脂指标、治疗效果、血清炎症因子水平,观察三组患者用药期间不良反应发生情况。结果:高剂量联合组、中剂量联合组治疗总有效率高于低剂量联合组(P0.05)。治疗后,高剂量联合组、中剂量联合组的总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平低于低剂量联合组,高密度脂蛋白胆固醇(HDL-C)水平高于低剂量联合组(P0.05)。治疗后三组患者的血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)水平随着剂量的升高而降低(P0.05)。低、中、高剂量联合组不良反应发生率比较无统计学差异(P0.05)。结论:采用10 mg和20 mg的瑞舒伐他汀联合通心络胶囊治疗冠心病合并高脂血症疗效确切,可有效改善患者血脂水平,无严重不良反应发生,且对炎症因子的改善效果成剂量依赖性,医师可根据临床实际选择用药剂量。     

载脂蛋白E基因多态性检测对ACS患者降脂疗效的影响

目的:探究载脂蛋白E(ApoE)基因多态性检测在急性冠脉综合征(ACS)患者降脂治疗的中应用价值。方法:选取2019年2月~2020年6月180例ACS患者,采用随机数字表法分为A、B、C共3组各60例,各组患者均接受ApoE基因多态性检测,并根据Sanger法测序判断ApoE基因表型(E2、E3、E4表型),A组予以瑞舒伐他汀口服(10 mg/d),B组予以瑞舒伐他汀强化治疗(20 mg/d),C组予以瑞舒伐他汀(10 mg/d)+依折麦布(10 mg/d)口服,连续治疗1个月,评价3组各基因表型血脂[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL-C)]改善情况、LDL-C达标率,记录药物副反应,所有患者随访1个月,统计心血管不良事件(MACE)发生情况。结果:3组ApoE基因E2、E3、E4表型构成比无显著差异(P>0.05)。治疗后,各组不同ApoE基因表型TC、TG、LDL-C水平均较治疗前下降,且变化率比较差异有统计学意义(P<0.05),表现为E2型>E3型>E4型;其中,3组E2表型TC、TG、LDL-C水平变化率无显著差异(P>0.05);B组、C组E3表型TC、TG、LDL-C水平变化率均显著高于A组(P<0.05),但B组、C组各指标变化率比较差异无统计学意义(P>0.05);3组E4表型TC、TG、LDL-C水平变化率比较差异有统计学意义(P<0.05),且表现为C组>B组>A组。治疗后,A组LDL-C达标率为61.67%,显著低于B组的85.00%、C组的90.00%(P<0.05);其中,3组E2表型LDL-C达标率比较无显著差异(P>0.05),A组E3表型LDL-C达标率显著低于B组、C组(P<0.05),A组、B组E4表型LDL-C达标率低于C组(P<0.05)。治疗期间,仅B组出现1例ALT超出正常上限3倍,停药后可恢复正常。3组MACE发生率比较差异有统计学意义(P<0.05),表现为A组发生率18.33%明显高于B组5.00%、C组3.33%(P<0.05),但3组E2、E4型MACE发生率均无明显差异(P>0.05),而A组E3型MACE发生率高于B组、C组(P<0.05)。结论:ACS患者降脂疗效与ApoE基因表型有关,对E2表型单用瑞舒伐他汀即可取得良好降脂效果,对E3表型强化瑞舒伐他汀或联合依折麦布治疗较单用瑞舒伐他汀均能提高降脂效果,而对E4表型联合依折麦布降脂效果优于单用瑞舒伐他汀或强化治疗。     

16S rDNA测序研究高脂饮食诱导的高脂血症大鼠肠道菌群变化

目的 通过高脂饮食诱导大鼠高脂血症,采用16S rDNA测序检测高脂血症大鼠肠道菌群变化情况.方法 SD大鼠20只(清洁级),按体质量随机分为模型组和对照组,对照组大鼠给予维持饲料,模型组大鼠给予高脂饲料.1周后检测血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C...     

南瓜多糖对糖尿病大鼠血糖、血脂及氧化应激能力的影响

目的:观察南瓜多糖对实验性糖尿病大鼠血糖、血脂及氧化应激能力的影响。方法:用两次注射四氧嘧啶(alloxan)诱导糖尿病大鼠模型,将SD大鼠40只随机分为4组(n=10):即正常对照组、糖尿病组、消渴丸组和南瓜多糖组,消渴丸组用消渴丸(200 mg/kg)灌胃,南瓜多糖组行南瓜多糖(500 mg/kg)灌胃共8周,测定糖尿病大鼠血糖(BG)、血脂,测定血清中超氧化物歧化酶(SOD)、过氧化氢酶(CAT)活性以及丙二醛(MDA)含量。结果:糖尿病组大鼠BG、总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白(LDL)含量均升高(P0.01),高密度脂蛋白(HDL)含量降低(P0.05),SOD和CAT的活性明显降低,而MDA的含量明显增加(P0.01);消渴丸组和南瓜多糖组大鼠BG、TC、TG和LDL-C降低,HDL-C升高(P0.05),SOD和CAT的活性明显的提高,MDA的含量明显减少(P0.01)。结论:南瓜多糖具有降低糖尿病大鼠血糖、血脂和增强氧化应激能力的作用。     

Serum and gene expression levels of leptin and adiponectin in rats susceptible or resistant to diet-induced obesity

The aim of the present study was to identify the role of leptin and adiponectin in the development of resistance or susceptibility to diet-induced obesity in rats. For this purpose, male Wistar rats were fed with standard laboratory diet (control group) or cafeteria diet. After 15 days, two groups of rats with different response respect to the cafeteria diet were identified, and were assigned as diet-induced obesity (DIO) and diet resistant (DR) rats. The high-fat diet induced a very significant increase in both body and fat mass weight in DIO group. However, DR rats, gained even less weight than control-fed animals. Food intake was increased in cafeteria-fed rats (both DIO and DR) in comparison to control group; but hyperphagia was higher in DIO rats. In addition, feed efficiency (the ratio of weight gained to calories consumed) was significantly decreased in DR as compared to DIO rats. Regarding leptin, a significant increase in both adipose tissue gene expression and serum levels was observed in DIO rats in comparison with other groups (control and DR). A significant increase in both adiponectin circulating levels and adipose tissue mRNA expression was also observed in DIO animals as compared with the other groups. These data suggest that the susceptibility to obesity of DIO rats might be secondary, at least in part, to an earlier development of leptin resistance, which could lead to alterations in food intake (hyperphagia) and energetic metabolism. However, neither changes in leptin or adiponectin seem to be involved in the adaptive mechanisms that confer resistance to high fat intake.     

有氧运动与饮食控制对2型糖尿病大鼠肝chemerin及其受体CMKLR1的影响

目的：研究4周有氧运动与饮食控制对2型糖尿病（DM）大鼠肝chemerin及其受体趋化因子样受体1（CMKLR1）的影响及其在改善糖脂代谢中的影响。方法：50只雄性SD大鼠随机分为正常对照组（Con,n=6）和糖尿病造模组（n=44）。采用高脂高糖饲料联合小剂量链脲佐菌素（STZ）（30 mg/kg）的方法制备2型糖尿病模型大鼠。造模成功的DM大鼠随机分为4组（n=6）：糖尿病对照组（DM）、糖尿病运动组（EDM）、改喂普通饲料的糖尿病饮食控制组（NDM）和糖尿病运动+饮食控制组（ENDM）。运动组大鼠进行为期4周中等强度跑台有氧运动,每周运动6 d。采用罗氏血糖仪检测大鼠空腹血糖（FBG）,全自动生化分析仪检测大鼠血清总胆固醇（TC）、甘油三酯（TG）和低密度脂蛋白（LDL）水平,real time PCR和Western blot分别检测大鼠肝chemerin、CMKLR1的mRNA和蛋白水平。结果：DM大鼠FBG和血清TC、TG、LDL水平显著升高的同时,肝chemerin和CMKLR1的mRNA和蛋白水平显著增加;4周有氧运动和/或饮食控制显著降低EDM、NDM和ENDM组FBG和血清TC、TG、LDL的同时,显著降低这3组大鼠的肝chemerin蛋白水平,其中ENDM组降低最显著（P<0.01）;NDM和ENDM组大鼠的肝CMKLR1蛋白水平升高（P<0.01）。结论：4周有氧运动和/或饮食控制降低2型糖尿病大鼠的肝chemerin蛋白水平、增加CMKLR1蛋白水平,这可能与其改善糖尿病大鼠的糖脂代谢有关。     

Meal Pattern Analysis of Diet‐Induced Obesity in Susceptible and Resistant Rats

Objective: To characterize the meal patterns of free feeding Sprague‐Dawley rats that become obese or resist obesity when chronically fed a high‐fat diet. Research Methods and Procedures: Male Sprague‐Dawley rats (N = 120) were weaned onto a high‐fat diet, and body weight was monitored for 19 weeks. Rats from the upper [diet‐induced obese (DIO)] and lower [diet‐resistant (DR)] deciles for body‐weight gain were selected for study. A cohort of chow‐fed (CF) rats weight‐matched to the DR group was also studied. Food intake was continuously monitored for 7 consecutive days using a BioDAQ food intake monitoring system. Results: DIO rats were obese, hyperphagic, hyperleptinemic, hyperinsulinemic, hyperglycemic, and hypertriglyceridemic relative to the DR and CF rats. The hyperphagia of DIOs was caused by an increase in meal size, not number. CF rats ate more calories than DR rats; however, this was because of an increase in meal number, not size. When expressed as a function of lean mass, CF and DR rats consumed the same amount of calories. The intermeal intervals of DIO and DR rats were similar; both were longer than CF rats. The nocturnal satiety ratio of DIO rats was significantly lower than DR and CF rats. The proportion of calories eaten during the nocturnal period did not differ among groups. Discussion: The hyperphagia of a Sprague‐Dawley rat model of chronic diet‐induced obesity is caused by an increase in meal size, not number. These results are an important step toward understanding the mechanisms underlying differences in feeding behavior of DIO and DR rats.     

Role of adipogenic and thermogenic genes in susceptibility or resistance to develop diet-induced obesity in rats

The aim of the present work was to assess whether changes in adipose tissue gene expression related with adipogenesis and/or thermogenesis could be involved in the mechanism conferring susceptibility or resistance to develop obesity in high-fat fed outbreed rats. For this purpose, male Wistar rats were fed with standard laboratory diet (control group) or high fat diet. After 15 days, two groups of rats with significant differences on body weight gain in response to the high fat diet were characterized and identified as diet-induced obesity (DIO) and diet resistant (DR) rats. A significant increase in visceral white adipose tissue (WAT) PPARgamma and aP2 (p < 0.05) mRNA levels associated to a decrease in RARgamma expression (p < 0.05) was observed in DIO rats, suggesting an increase of adipogenesis. Furthermore, our data showed a marked increase in brown adipose tissue (BAT) of UCP1 mRNA in DIO animals (p < 0.01) (without affecting PGC-1alpha gene expression), whereas no changes were found in WAT UCP2 gene expression. All these data suggest that the variations found in the expression pattern of PPARgamma, aP2 and RARgamma by high-fat diet could be involved, at least in part, in the differences in body weight gain and adiposity observed between DR and DIO animals. The compensatory adaptations through the increase in energy expenditure by changes on the expression levels of UCP1 seem not to be enough to avoid the obesity onset in the DIO group.     

非酒精性脂肪肝病大鼠肝脏SOCS-3 的表达与吡格列酮干预研究

目的:探讨SOCS-3在非酒精性脂肪肝病(NAFLD)发病中的作用以及吡格列酮的干预作用。方法:29只雄性SD大鼠随机分为正常对照组(8只),高脂饮食组(21只)。饲养8周后,从高质饮食组随机抽取5只大鼠证实造模成功后,将该组余下的16只大鼠继续以高脂饲料喂养,并随机分为NAFLD对照组(8只);吡格列酮干预组(8只),予以吡格列酮3mg·kg-·1d-1灌胃。16周末,处死所有大鼠,检测血糖、血胰岛素、血脂、肝脏SOCS-3 mRNA和SREBP-1c mRNA表达及肝脏病理学。结果:与正常对照组相比,NAFLD组血糖、血胰岛素、血脂、肝脏脂肪变水平及肝组织SOCS-3 mRNA、SREBP1c mRNA表达显著上调。吡格列酮干预组SOCS-3 mRNA、SREBP-1c mRNA表达较NAFLD组下调,且血糖、血胰岛素、血脂、肝脏脂肪变水平下降。SOCS-3 mRNA表达水平与胰岛素抵抗指数、SREBP-1c mRNA表达水平、肝脂肪变成显著正相关。结论:SOCS-3可能通过胰岛素抵抗及上调肝组织SREBP-1c mRNA表达参与NAFLD发病,吡格列酮能抑制肝脏SOCS-3的表达,对NAFLD有一定治疗作用。     

非酒精性脂肪性肝病大鼠肝脏PPAR-γ的表达

目的:研究PPAR-Y在非酒精性脂肪性肝病(NAFLD)大鼠肝脏组织中的表达,探讨非酒精脂肪性肝病可能的发病机制.方法:雄性SD大鼠30只,随机分为A(正常组)15只普通饮食,B(高脂组)15只高脂饮食.8周后,自两组各随机抽取2只大鼠处死,光镜观察证实脂肪肝造模成功,继续喂养4周后处死所有大鼠,取血清做免疫生化检查,取肝组织标本,分别以光镜观察做出NAS评分,免疫组化和PCR法检测肝组织PPAR-Y蛋白的表达.结果:1.高脂饮食可以成功的复制NAFLD的大鼠模型;2.血清GLU、TC、TG、HDL-C、LDLC在高脂组表达量较正常组明显升高,差异具有统计学意义(P＜0.05);3.免疫组化显示:高脂组PPAR-Y表达量较正常组升高;结论:1.高脂饮食可成功复制NAFLD模型;2.PPAR-Y在NAFLD大鼠肝脏成脂性改变中具有重要作用.     

Effect of sibutramine on regional fat pads and leptin levels in rats fed with three isocaloric diets

AIM: The aim of the study was to investigate: a) the differential effect of the three main macronutrients on food intake, fat depots and serum leptin levels and b) the impact of sibutramine on the above parameters in rats fed ad libitum with three isocaloric diets. METHODS: Three groups of male Wistar rats (n = 63) were fed with a high fat diet (HFD), a high carbohydrate diet (HCD) or a high protein diet (HPD) for 13 weeks. In the last three weeks, each group was divided into three subgroups and received sibutramine (S) either at 5 mg/kg or 10 mg/kg, or vehicle. Food intake was measured daily during the last week of the experiment; perirenal and epididymal fat and fat/lean ratio were calculated and serum leptin was assayed. RESULTS: HFD-fed rats demonstrated elevated food intake and higher regional fat depots. S at 10 mg/kg decreased food intake in the HFD and epididymal fat in the HCD group. S also reduced perirenal fat in the HCD and HPD groups. Leptin levels were higher in rats fed with either the HFD or the HPD compared to those fed with the HCD. Moreover, S at 10 mg/kg decreased serum leptin levels in the HPD group. CONCLUSIONS: Results suggest a preferential effect of S on perirenal visceral fat and support the view that body fat loss is greater when its administration is accompanied by a HCD diet. No effect of S on leptin levels was found, besides that expected as a result of the decrease in body fat.     

Different functional responsibility of the small intestine to high-fat/high-energy diet determined the expression of obesity-prone and obesity-resistant phenotypes in rats

The objective of the present experiment was to assess the involvement of small intestine in expression of susceptibility or resistance to the high-fat/high-energy diet. The investigation was carried out in adult male Sprague-Dawley rats fed either standard laboratory diet (3.2 kcal/g, 9.5 % fat) or high-fat (HF) diet (4.04 kcal/g, 30 % fat) for 4 weeks as well as in HF rats that were retrospectively designated on the bases of their higher or lower weight gain as sensitive (DIO) or resistant (DR) to obesity. Our results revealed in HF group significant increase in energy intake, food efficiency, weight gain and Lee s index of obesity. Moreover, in comparison with controls, a significantly increased duodenal and jejunal alkaline phosphatase (AP) and alpha-glucosidase activity as well as hypertrophy of jejunal mucosa (increased protein/DNA ratio) were observed in HF fed rats. In contrast, intestinal function was inversely related to energy intake or to the development of adiposity in DIO vs. DR rats. The DR rats had significantly greater AP and alpha-glucosidase activity and more pronounced suppression of energy intake than obese DIO rats. It indicates that the increase of enzyme activities and the lowered effectiveness of nutrient absorption might be a significant factor preventing the expression of obesity proneness. This information contributes to a better understanding of a complex interaction between HF diet feeding and small intestinal adaptability, which determines the energy homeostasis and predict the ability to resist or develop obesity in these phenotypes.